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Background: There are no approved small molecule drug therapies for human respiratory syncytial virus (hRSV), a
cause of morbidity and mortality in at-risk newborns, the immunocompromised, and the elderly. We have investigated as
a potential novel hRSV drug target the protein-protein interaction between the C-terminus of the viral phosphoprotein (P)
and the viral nucleocapsid protein (N), components of the ribonucleoprotein complex that contains, replicates,
and transcribes the viral RNA genome. Earlier work by others established that the 9 C-terminal residues of P are
necessary and sufficient for binding to N.
Methods: We used a fluorescence anisotropy assay, surface plasmon resonance and 2-D NMR to quantify the
affinities of peptides based on the C terminus of P for RNA-free, monomeric N-terminal-truncated N(13-391). We
calculated the contributions to the free energies of binding of P to N(13-391) attributable to the C-terminal 11
residues, phosphorylation of the C-terminal 2 serine residues, the C-terminal Asp-Phe, and the phenyl ring of the
C-terminal Phe.
Results: Binding studies confirmed the crucial role of the phosphorylated C-terminal peptide D(pS)DNDL(pS)LEDF
for binding of P to RNA-free, monomeric N(13-391), contributing over 90% of the binding free energy at low
ionic strength. The phenyl ring of the C-terminal Phe residue contributed an estimated -2.7 kcal/mole of the
free energy of binding, the C-terminal Asp-Phe residues contributed -3.8 kcal/mole, the sequence DSDNDLSLE
contributed -3.1 kcal/mole, and phosphorylation of the 2 Ser residues contributed -1.8 kcal/mole. Due to the
high negative charge of the C-terminal peptide, the affinity of the P C-terminus for N(13-391) decreased as the
ionic strength increased.
Conclusions: The results support the idea that the interaction of the C-terminal residues of P with N constitutes
a protein-protein interaction hotspot that may be a suitable target for small-molecule drugs that inhibit viral
genome replication and transcription.
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Human respiratory syncytial virus (hRSV) is a non-
segmented negative sense RNA virus in the order
Mononegavirales, the family Paramyxoviridae and the
genus Pneumovirus, and is the cause of severe respiratory
tract infections among newborns, immunocompromised
people, and the elderly [1]. Current treatments are limited
to antibody prophylaxis with palivizumab for high-risk
newborns, general antiviral therapy with ribavirin, and
supportive care. Efforts to develop anti-RSV vaccines and
new drugs to prevent and treat the disease have so far
been unsuccessful [2-4].
The genome of hRSV codes for 11 proteins. Four of
these, the polymerase (L), nucleocapsid protein (N),
phosphoprotein (P) and transcription anti-termination
factor (M2-1), along with the RNA genome, make up the
ribonucleoprotein (RNP) complex responsible for transcrip-
tion and replication of the RNA. Several types of low mo-
lecular weight compounds have been identified that appear
to target the RNP. Mutations conferring resistance to the
inhibitory effect of YM-53404 and related compounds on
viral replication were found in the polymerase L [5,6].
Mutations conferring resistance to RSV604 are found
in the nucleocapsid N protein [7]. Liuzzi et al. [8] iden-
tified inhibitors of the mRNA capping function of the L
protein, resistance mutations to which are found in the L
protein. Thus the RNP is a viable target for compounds
that inhibit RSV replication.
Several protein-protein interactions are involved in as-
sembly of RNP. The N protein forms helical oligomers
around which the RNA is wrapped [9,10]. P protein oligo-
merizes [11,12] and interacts with N [12-15], M2-1[16-20],
and L [21-23]. M2-1 is a tetramer [19,24] and interacts
with N [25-27] as well as P. These protein-protein in-
teractions may offer suitable targets for antiviral drug
discovery.
Protein-protein interactions can be difficult to disrupt
with low molecular weight drugs if the interactions occur
over a large, flat surface. Protein-protein interaction hot-
spots, confined areas with deep topological features, how-
ever, offer greater potential for drug discovery [28]. The
information available concerning the interaction of the C-
terminus of the RSV P protein with the N protein suggests
that this interaction may occur at such a hotspot. A puta-
tive P binding region on the N-terminal core domain of N
was identified by Galloux et al. [13], including Lys 46, Met
50, Ile 53, Ser 131, Arg 132, Tyr 135, Arg 150, and His
151. Mutations of several residues in this domain to ala-
nine reduced both viral RNA synthesis and the N-P inter-
action in vivo and in vitro. On the crystal structure of N,
these residues are clustered together, forming a potential P
binding site with a hydrophobic cavity surrounded by sev-
eral basic side chains. Remarkably, only the C-terminal 9
residues of P (Asp 233 to Phe 241) are necessary forbinding to N in pull-down assays [13,15]. Moreover,
changing just the C-terminal phenylalanine residue of
P to alanine abrogates both N binding and viral RNA
synthesis [13]. These observations strongly support the
existence of a P-N binding hotspot involving the C-
terminus of P and the aforementioned N-terminal core
domain of N.
The C-terminal 11 residues of P (Asp-Ser-Asp-Asn-
Asp-Leu-Ser-Leu-Glu-Asp-Phe) include 2 serine residues,
Ser 232 and Ser 237, both of which have been observed to
be phosphorylated, although the importance of their phos-
phorylation is unclear. Mazumder et al. [29] showed that
purified recombinant P was selectively phosphorylated on
Ser 237 by casein kinase II. Mazumder and Barik [30]
found that mutation of Ser 237 to Ala abrogated RNA
transcription by reconstituted RNP in vitro, whereas mu-
tation of Ser 232 to Ala had no effect. In contrast, Barik
et al. [31] found that Ser 232 was the major site of P phos-
phorylation when it was expressed in human cells or when
unphosphorylated recombinant P was treated with a crude
human cell extract. Sánchez-Seco et al. [32] found that Ser
232, not Ser 237, was the main site of phosphorylation
of recombinant P in vitro by casein kinase II. Villanueva
et al. [33] found that phosphorylation of P expressed in
human cells was mainly on Ser 232 and to a lesser extent
on Ser 237, based on the decreased level of phosphoryl-
ation when either residue was changed to Ala, but that
mutation of either of these residues had little effect on
viral transcription or replication. Only mutation of both
residues combined with mutation of other probable sites
of serine phosphorylation elsewhere in the protein sub-
stantially reduced, but did not completely eliminate, tran-
scription and replication. Finally, Lu et al. [34] found that
eliminating phosphorylation of Ser 232 and Ser 237 by
mutation reduced P phosphorylation by 80% in infected
cells, but had only modest effects on reporter gene expres-
sion and the N-P interaction. The mutant virus showed
impaired replication in rodents compared with the wild-
type virus, however. The inconsistencies in the results
reported in the literature on this topic do not allow us
to draw definitive conclusions regarding either the extent
of phosphorylation of Ser 232 and Ser 237 or the roles
of these residues in the functions of P, including its
interaction with N.
We have taken a quantitative biophysical approach to
investigate the P-N protein-protein interaction with re-
gard to the effect of phosphorylation of the C-terminal
N-binding peptide of P on residues 232 and 237 and the
importance of the C-terminal Phe residue. In the process,
we demonstrate 3 practical measurement systems –
fluorescence anisotropy, surface plasmon resonance,
and 2-D NMR - that can be used as the first steps in
drug discovery programs to identify inhibitors of the
interaction.
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Fluorescence anisotropy measurements of P C-terminal
peptide binding to N(13-391)
Peptides having the sequence of the C-terminal 11 residues
of RSV P protein (DSDNDLSLEDF) were labeled on the
N-terminus with the fluorophore BODIPY FL for fluores-
cence anisotropy-based measurements of binding to N(13-
391), an N-terminally truncated construct of RSV N
protein that does not oligomerize [35]. The truncation
makes the protein easier to overexpress in soluble form in
bacteria than full-length N. When purified from bacteria,
the truncated N proteins used in this study had no detect-
able RNA associated with them. One peptide was unpho-
sphorylated (BP1). The other was phosphorylated on
both serine residues (BP5), corresponding to Ser 232
and Ser 237 of the P protein. Both peptides bound to
the N(13-391) construct (Figure 1A). The affinity of
the doubly phosphorylated peptide BP5 (Kd = 78 ± 5
nM) was about 10 times that of the unphosphorylated
peptide BP1 (Kd = 760 ± 20 nM). This result indicatesFigure 1 Fluorescence anisotropy measurements of P C-terminal pe
full-length P. (A) Affinity of unphosphorylated and doubly phosphorylated
Data points and error bars represent the means and standard deviations, resp
points. The Kds for BP1 and BP5 were 760 ± 20 nM and 78 ± 5 nM, respectivel
affinity of BP5 for N(13-391). Kds were measured with N(13-391) concentration
Data points and error bars represent the best-fit Kds and the standard err
by full-length P protein. The IC50 was 180 ± 10 nM (best-fit value ± standathat phosphorylation of the serine residues in the
C-terminus of P is likely to affect the affinity of the
N-P binding interaction. The anisotropy change was
also larger for BP5 than BP1. Subsequent experiments
were performed with BP5 because of the lower N(13-391)
concentration required to perform competition experi-
ments and larger signal compared with BP1.
Considering the highly negative charge of the doubly
phosphorylated P C-terminal peptide due to the presence
of 2 phosphate groups and 5 acidic side chains within the
11 residue peptide, we reasoned that electrostatic interac-
tions with N would likely play a significant role in the inter-
action between them. Moreover, the putative P binding site
on N contains several basic amino acid side chains [13]. In
support of this hypothesis, we found that the affinity of BP5
for N(13-391) diminished as the ionic strength increased
(Figure 1B). Subsequent experiments were performed in a
low-ionic strength buffer in order to maximize the affinity
of BP5 for N(13-391), thereby minimizing the amount of
protein required.ptide binding to N(13-391), effect of KCl, and competition by
P-derived C-terminal peptides BP1 and BP5, respectively, for N(13-391).
ectively, of 3 replicates. The error bars are mostly hidden by the data
y (best-fit value ± standard error of fit). (B) Effect of KCl concentration on
s ranging from 1.95 to 2000 nM in triplicate. The data were fit as above.
ors of the fits, respectively. (C) Inhibition of BP5 binding to N(13-391)
rd error of fit).
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to N(13-391) measured by fluorescence anisotropy
The effect of phosphorylation of each of the two serine
residues in the C-terminal peptide on its affinity for N
(13-391) was investigated by competition with BP5 bind-
ing (Table 1). Phosphorylation of either serine residue
substantially increased the affinity of the peptide com-
pared with the unphosphorylated peptide, 7-fold for the
N-terminal serine and 10-fold for the C-terminal serine.
Phosphorylation of both serine residues resulted in an
additional affinity enhancement of approximately 3-fold
greater than observed for phosphorylation of one residue.
As a result, the affinity of the doubly phosphorylated pep-
tide was 20-25-fold higher than the affinity of the unpho-
sphorylated peptide. This is consistent with the above
observation that the affinity of doubly phosphorylated
BP5 is 10-fold higher than the affinity of unphosphory-
lated BP1.
The Kds of the peptides in the fluorescence anisotropy
experiments are approximately ½ the IC50s because the
N(13-391) concentration used was equal to its Kd with BP5.
Therefore, the Kds of DSDNDLSLEDF and D(pS)DNDL
(pS)LEDF were about 7.6 and 0.34 μM, respectively. These
Kds are considerably higher than the Kds of the same pep-
tides bearing an N-terminal BODIPY FL fluorophore, BP1
(0.76 μM) and BP5 (0.078 μM), respectively. This is most
likely due to the hydrophobic character of the fluorophore,
which tends to enhance the affinity of a ligand as long as
the fluorophore does not cause a steric clash.
Effect of changing the P C-terminal peptide’s C-terminal
residue on binding to N(13-391) measured by fluorescence
anisotropy
The C-terminal phenylalanine residue of P is crucial for
binding of P to N, and mutation to alanine abrogatesTable 1 Competition by RSV-P C-terminal-derived
peptides with BP5 binding to RSV-N(13-391)
IC50 (μM) ± standard error
Peptide sequence Fluorescence anisotropy SPR
DSDNDLSLEDF 15.3 ± 0.4 230 ± 30
DSDNDLSLEDA >200 ND
D(pS)DNDLSLEDF 2.17 ± 0.04 44 ± 3
DSDNDL(pS)LEDF 1.51 ± 0.03 31 ± 2
D(pS)DNDL(pS)LEDF 0.61 ± 0.01, 0.74 ± 0.02 13.6 ± 0.3
D(pS)DNDL(pS)LEDA 69 ± 2 ND
DF 1450 ± 50 ND
Competition was measured by the fluorescence anisotropy assay and with N
(13-391) binding to P by SPR. Competitor peptide concentrations ranged from
0.2 to 200 μM. The IC50 for D(pS)DNDL(pS)LEDF was measured twice using
fluorescence anisotropy. IC50s from the fluorescence anisotropy assay are
approximately twice the Kds of the competitors because the N(13-391)
concentration was set at the Kd for the interaction of N(13-391) with BP5. ND,
not done.binding and viral replication [13]. The effect of changing
the C-terminal Phe residue to Ala on competition by
the P C-terminal peptide with BP5 binding to N(13-391)
was substantial (Table 1). For unphosphorylated peptides,
the IC50 increased by more than 13-fold when Phe was
changed to Ala. The IC50 of the Ala-modified peptide
exceeded the highest concentration tested (200 μM). In-
hibition by 200 μM peptide was about 25%, so the true
IC50 can be estimated to have been approximately 600
μM, assuming a Hill slope of 1, which was typical for these
measurements. Thus the IC50 shifted upward about 40-
fold when Phe was replaced with Ala in the unphosphory-
lated peptide. For the phosphorylated peptides, changing
Phe to Ala resulted in an upward shift of the IC50 by ap-
proximately 100-fold. These results are consistent with the
literature showing that the C-terminal Phe of P is a crucial
binding determinant for its interaction with N.
Competition by full-length P protein with P C-terminal
peptide binding measured by fluorescence anisotropy
Full-length P protein produced in insect cells was tested
for its ability to compete with BP5 binding to N(13-391).
As determined by mass spectrometry, the P protein con-
sists of a mixture of unphosphorylated, singly and doubly
phosphorylated species, with the singly phosphorylated
species most abundant (data not shown). The locations of
the phosphorylated residues are unknown and may differ
between molecules. Figure 1C shows that this P protein
competed with an IC50 of 180 nM (Kd ~90 nM). Interest-
ingly, this is only about 4-fold greater affinity than was
measured for the doubly phosphorylated C-terminal
peptide D(pS)DNDL(pS)LEDF. This observation is con-
sistent with the hypothesis that the interaction of P with N
is largely, if not entirely, determined by the last several
residues at the C-terminus of P.
Surface plasmon resonance measurements
The P C-terminus-derived peptides were tested for their
ability to compete with soluble N(13-391) binding to
immobilized P using SPR. The SPR results are consistent,
in terms of rank order of potencies, with the results from
the fluorescence anisotropy measurements, although the
IC50s are higher for the SPR measurements (Figure 2 and
Table 1). This is likely due to the higher ionic strength
used in the SPR experiments (see Figure 1B). The SPR re-
sults demonstrate that the fluorescence anisotropy assay
of the inhibition by peptides of BP5 binding to N(13-391)
is a reliable surrogate for the inhibition by peptides of N
(13-391) binding to P.
2-D NMR measurements
The importance of the C-terminal Phe residue for N
binding was studied by measuring the ability of the P-
derived C-terminal dipeptide Asp-Phe to compete with
Figure 2 Inhibition of N(13-391) binding to immobilized P protein by D(pS)DNDL(pS)LEDF peptide measured by SPR. Concentrations of
the peptide are indicated on the figure. The IC50 (curve shown in inset) was 13.7 ± 0.3 μM (best-fit value ± standard error of the best-fit value). The
concentration of N(13-391) was 100 nM. Injection spikes have been deleted from the image for clarity.
Figure 3 Binding of Asp-Phe (left) and D(pS)DNDL(pS)LEDF (right) to N(31-252). (A) Contour plots of backbone amide resonances of 0.15 mM
15N-labeled N(31-252) obtained from two-dimensional [15N, 1H] TROSY spectra recorded at a range of ligand concentrations. Numbered resonances
correspond to the graphs in panel B. Dotted arrows denote the putative directions of shift for resonances 1 and 7. The missing resonances of 1 and 7
in the presence of 0.1 mM D(pS)DNDL(pS)LEDF indicate the binding interaction is in the intermediate exchange regime [36]. (B) Chemical shift
perturbations Δδ(N, H)obs of selected amide resonances of 15N-labeled N(31-252) as a function of ligand concentration. The symbols represent
the experimental data and the lines are global best-fit theoretical curves for a simple binding isotherm. The best-fit values ± standard error of
the fit of Kds were 2.6 ± 0.3 mM for Asp-Phe (left) and 74 ± 4 μM for D(pS)DNDL(pS)LEDF (right).
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(Table 1). Two-dimensional NMR experiments with
15N-labeled N(31-252) confirmed that this dipeptide
binds to N(31-252), as shown by the shift in position of
several crosspeaks (Figure 3A). When the longer peptide
D(pS)DNDL(pS)LEDF was used, additional crosspeaks
shifted position (Figure 4). This result demonstrates that
the longer peptide makes more contacts with the P binding
site of N(31-252) than the dipeptide. The Kds of Asp-Phe
and D(pS)DNDL(pS)LEDF measured by NMR were 2.6
mM and 74 μM, respectively (Figure 3B). These Kds were
higher than those measured by the fluorescence anisotropy
assay because of the higher ionic strength of the buffer
in which the NMR experiments were performed. As ex-
pected, this ionic strength effect was greater for the more
highly charged peptide D(pS)DNDL(pS)LEDF than for
Asp-Phe.
Discussion
Using the relationships ΔG= RT ln Kd and IC50 = 2 × Kd,
we can obtain approximate values for ΔG of binding for
the components of the C-terminal peptide of P to RNA-
free N(13-391) in 10 mM Tris-HCl (pH 7.5) at 21°C. This
calculation shows that Asp-Phe (DF) contributes -3.8
kcal/mole out of -8.7 kcal/mole for D(pS)DNDL(pS)
LEDF. The contribution of the phenyl ring of the Phe
residue can be estimated by comparing ΔG of binding
for D(pS)DNDL(pS)LEDF (-8.7 kcal/mole) to that for D
(pS)DNDL(pS)LEDA (-6.0 kcal/mole), hence ΔΔG= -2.7
kcal/mole, corresponding to a Kd for the phenyl ring of 10
mM. The ΔG of binding attributable to DSDNDLSLE can
be estimated by subtracting the ΔG of binding of DF (-3.8
kcal/mole) from the ΔG of binding of DSDNDLSLEDF
(-6.9 kcal/mole) to obtain a value of -3.1 kcal/mole for
this part of the C-terminal peptide, which contains 5 acidic
side chains (not counting the C-terminus) that could inter-
act with basic residues in the P binding site of N(13-391).
The ΔG of binding contributed by phosphorylation of bothFigure 4 Backbone amide resonances of 15N-labeled N(31-252) from t
peptide ligand. The concentration of N(31-252) was 0.15 mM. (A) 2 mM AsSer residues can be estimated by comparing ΔG of binding
for DSDNDLSLEDF (-6.9 kcal/mole) to that for D(pS)
DNDL(pS)LEDF (-8.7 kcal/mole), hence ΔΔG= -1.8 kcal/
mole. Interestingly, these estimates indicate that the phenyl
ring of the C-terminal Phe residue contributes more free
energy of binding than both phosphate moieties, that over
40% of the free energy of binding of D(pS)DNDL(pS)LEDF
comes from the DF dipeptide, and that over 90% of the free
energy of binding of the full-length P used in this experi-
ment can be attributed to the D(pS)DNDL(pS)LEDF pep-
tide. These calculations are oversimplified by not taking all
factors into account, such as the fact that DF and D(pS)
DNDL(pS)LEDF have free N-termini that are parts of
amide bonds in the longer peptides and the full-length
protein, respectively, and the unknown phosphorylation
status of the C-terminal serine residues of the full-length
P. Nevertheless, the calculations are helpful in demon-
strating that most of the affinity of P for N(13-391) is due
to the last several residues at the C-terminus of P, and that
much of the affinity of these C-terminal residues is due
to the binding of the last 2 residues. This observation is
consistent with the idea that the N-P interaction can be
considered to be a protein-protein interaction hotspot.
The relatively small energetic contribution of Ser 232
and Ser 237 phosphorylation to the affinity of D(pS)
DNDL(pS)LEDF for binding to N(13-391) (-1.8 kcal/mole),
combined with the observation that phosphorylation of ei-
ther of the serine residues has nearly as much effect on the
affinity as phosphorylation of both, suggests a possible ex-
planation for the inconsistent results reported in the litera-
ture on the importance of Ser 232 and Ser 237 for RSV
transcription and replication (see Introduction). The extent
to which P C-terminal phosphorylation affects RNP assem-
bly will depend on the local concentrations of the P and/or
N proteins. If at least one of these concentrations is well in
excess of the N-P binding Kd when P is unphosphorylated,
then the interaction will not be significantly affected by
phosphorylation. In contrast, if the concentrations of bothwo-dimensional [15N, 1H] TROSY spectra. Blue, no ligand. Red,
p-Phe. (B) 0.3 mM D(pS)DNDL(pS)LEDF.
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ation, by lowering the Kd, will drive the binding interaction.
It may be that the N and P concentrations present in the
various reported experiments differed sufficiently for the
extent of P C-terminal phosphorylation to affect the
efficiency of RNP assembly differently between them. For
example, Mazumder and Barik [30] used in vitro reconsti-
tuted RNP, whereas Lu et al. [34] used infected cells.
In a comparison of the sequences of residues 231-241
in 163 publicly available sequences of RSV P protein in
PubMed, the 3rd-to-last residue, Glu 239, is frequently
conservatively replaced by Asp, and there is one instance
each of Asn 234 being replaced by Asp and Ser 237 being
replaced by Leu. The other residues are invariant. Simi-
larly, the residues of N protein identified by Galloux et al.
[13] as being involved in binding to P - Lys 46, Met 50, Ile
53, Ser 131, Arg 132, Tyr 135, Arg 150, and His 151 – are
completely conserved among 126 published full-length N
sequences in PubMed. This high degree of sequence con-
servation is consistent with the importance of P residues
231-241 and the aforementioned N residues for binding of
P and N.
Conclusion
Three biophysical methods were used in this research: (1)
a fluorescence anisotropy-based binding assay to measure
competition by P-derived peptides and full-length P with
binding of BP5 (D(pS)DNDL(pS)LEDF labeled on the
N-terminus with BODIPY FL) to N(13-391), (2) surface
plasmon resonance (SPR) to measure the competition by
P-derived peptides with binding of N(13-391) to P, and (3)
2-D NMR to measure direct binding of Asp-Phe D(pS)
DNDL(pS)LEDF to N(31-252). Each of these methods is
suitable for screening compounds for binding to the N-P
protein-protein interaction hotspot. Because of their
relatively low throughput, SPR and NMR are most useful
for screening small libraries of hundreds of very low
molecular weight (<300 Da) fragments. The fluores-
cence anisotropy assay can be used to screen much
larger libraries consisting of hundreds of thousands of
compounds because it is a high-throughput assay. The
active samples from such a screen could then be coun-
terscreened to remove false positives due to detection
artifacts using SPR and/or NMR. Thus the methods used
here could be used to begin a drug discovery program
aimed at identifying competitive inhibitors of the binding
of RSV P protein to N that work by occupying the P bind-
ing site of N.
Methods
Peptides
Oligopeptides corresponding to residues 231-241 of RSV
P protein, including phosphorylation, were synthesized and
purified by Biopeptide Co. Inc. (San Diego, CA). Purities ofpeptides were at least 95%. N- and C-termini were un-
capped. Asp-Phe was from Sigma.
Preparation of BODIPY-FL-labeled peptides 1 and 5
(BP1 and BP5)
One μmole (1.3 mg) of peptide 1 (DSDNDLSLEDF) and
10 μmoles (5 mg) of BODIPY FL sulfosuccinimidyl ester
(SSE) (Life Technologies) were dissolved in 100 μl of fresh
0.1 M NaHCO3 and reacted for 1 hour in darkness at room
temperature. Peptide 5 (D(pS)DNDL(pS)LEDF), where (pS)
is phosphoserine, (1.2 mg, 0.84 μmole) and 10 μmoles of
BODIPY FL SSE were dissolved in 400 μl of fresh 0.2 M
NaHCO3 + 50 μl of dimethyl sulfoxide and reacted for 2.75
hours at room temperature. In each case, the solution was
applied to a 1 × 18-cm column of Sephadex LH-20 (Sigma)
equilibrated with water. The column was eluted with water
and fractions were collected. Liquid chromatography-mass
spectrometry (LC-MS) was used to select fractions having
the expected mass for the labeled peptide (1543 Da for
BP1, 1701 Da for BP5) and little or no unlabeled peptide.
For BP5, LC-MS also showed evidence of a 1682 Da
species, suggesting loss of a fluorine atom, probably during
the analysis. The concentration of the peptides was deter-
mined by the BODIPY FL absorbance at 504 nm using an
extinction coefficient in water of 91,000 M-1cm-1.
Mass spectrometry of peptides
The LC-MS analysis was performed on a Triple TOF
5600+ (AB Sciex, Redwood City, CA) equipped with a
DuoSpray Ion Source and a Shimadzu LC 20-AD HPLC sys-
tem (Shimadzu Scientific Instruments, Marlborough, MA).
Separation was achieved on a 2.1 x 30 mm XBridge C18
column (Waters, Milford, MA) with a gradient of aceto-
nitrile (5-90%) in 0.1% formic acid for 3 min following 1
min at 5% acetonitrile at a flow rate of 0.4 ml/min and col-
umn temperature of 30°C. LC-MS data was acquired in
the TOF MS mode for m/z + from 100 to 2000. Nebulizer
gas (GS1), heater gas (GS2), and curtain gas were set at
60, 70, and 30 psi, respectively. The source temperature
was 600°C. Ion spray voltage was 5500 V. Declustering
voltage was 100 V.
Fluorescence anisotropy assays
Samples of 10 μl containing peptides and proteins as
indicated were prepared in buffer composed of 10 mM
Tris-HCl (pH 7.5) +0.01% Brij-35 detergent (Pierce Surfact-
Amps-35, Thermo Fisher Scientific, Rockford, IL) in low-
volume 384-well black polystyrene assay plates (Thermo
Fisher Scientific, Hudson, NH). After a 5 minute incu-
bation, fluorescence anisotropy was measured with a
Pherastar plate reader (BMG Labtech, Cary, NC) equipped
with a filter module having a 485 nm excitation filter and
520 nm emission filters with polarizers. The focal height
was 10.8 mm. Each measurement used 50 flashes. The
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392 and 366 in order to produce an anisotropy of about
0.03 in the absence of binding.
For measurements of fluorescent peptide Kds with RSV-
N(13-391), BP1 and BP5 concentrations were 100 nM and
25 nM, respectively. The averages of triplicate fluorescence
anisotropy measurements made at each RSV-N(13-391)
concentration were fit to the equation
y ¼ yo þ a N½ = Kd þ N½ ð Þ
where y is the anisotropy, yo is the anisotropy of peptide
alone, [N] is the RSV-N(13-391) concentration, and yo +
a is the anisotropy of fully bound peptide. The Kds were
not corrected for 18% and 14% decreases in the fluores-
cence intensities of BP1 and BP5, respectively, upon
binding.
For IC50 measurements by competitors, the BP5 and
RSV-N(13-391) concentrations were 25 and 75 nM,
respectively. The averages of triplicate anisotropy measure-
ments made at each competitor concentration were used to
calculate % inhibition using the equation
% inhibition ¼ 100 1 – r–rminð Þ= rmax–rminð Þ½ 
where r is the anisotropy at the competitor concentra-
tion, rmin is the anisotropy with no RSV-N(13-391), and
rmax is the anisotropy with no competititor. The % in-
hibition values were used to determine the IC50 by non-
linear regression using the equation
% inhibition ¼ 100 C½ b= IC50 þ C½ b
 
where [C] is the competitor concentration and b is the
Hill slope.
All fluorescence anisotropy measurements were per-
formed at ambient temperature, approximately 21°C.
Surface plasmon resonance (SPR)
SPR experiments were performed on a Biacore T200
using Series S NTA sensor chips (GE Healthcare). His10-
RSV P protein was immobilized on the surface using the
nickel-capture amine-couple approach. The immobilization
buffer consisted of 10 mM HEPES-NaOH (pH 7.5), 150
mM NaCl, 0.1 mM EDTA, 1 mM tris(2-carboxyethyl)
phosphine hydrochloride (TCEP) and 0.005% (v/v) Tween-
20. The surface was activated for His-tag capture by inject-
ing 500 μM NiSO4 for 60 s at a flow rate of 30 μl/min.
Subsequent activation for amine coupling was achieved by
injecting a mixture of 200 mM 1-ethyl-3-[3-dimethylami-
nopropyl]carbodiimide and 50 mM N-hydroxysuccinimide
(NHS) for 7 min at flow rate 10 μl/min. His10-P protein
was diluted in immobilization buffer to a final concen-
tration of 6 μM. The protein was immobilized to ~6000
resonance units (RU) by applying short (1-4 μl) pulsesof protein at 5 μl/min until the desired immobilization
level was achieved. Residual NHS was blocked by a 7 min
injection of 0.1 M Tris-HCl (pH 8.0) at 10 μl/min. Finally,
the nickel was stripped from the surface using a 60 s injec-
tion of 350 mM EDTA at a flow rate of 30 μl/min.
Inhibition assays were carried out in 20 mM HEPES-
NaOH (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 mM TCEP,
0.005% (v/v) Tween 20 and 1% (v/v) DMSO at a constant
concentration of 100 nM RSV N(13-391). Peptides were
mixed with N(13-391) in a 9-point concentration series of
2-fold dilutions from a top concentration of 100 μM. Three
blanks were included for determining the maximum bind-
ing response. Samples were allowed to come to equilibrium
for 30 min before injection at 40 μl/min for 60 s followed
by a 180 s dissociation period. To monitor surface integrity,
positive and negative controls consisting of 100 nM RSV
N(31-252) and assay buffer, respectively, were run every
12 cycles. To correct for DMSO mismatches, three cy-
cles of 8 solvent correction samples in the range 0-2%
(v/v) DMSO were run at the beginning, middle and end
of the experiment.
Data were analyzed using the Biacore T200 Evaluation
Software V 2.0. Sensorgram data was reference-subtracted
and solvent-corrected before the binding report point was
extracted for each concentration at a time 4 s before the
end of the injection. These data were used to calculate the
percent inhibition according to the following equation: %
Inhibition = 100*(1 – Response(conc)/Response_max),
where Response_max is the average report point extracted
from the 3 blank runs. Percent inhibition was plotted ver-
sus concentration and fit to a 4-parameter logistic Hill
Equation (see above) for determining the peptide IC50.
2-D NMR
NMR spectra were acquired at 298 K with a 600 MHz
NMR instrument (Bruker, Billerica MA) equipped with an
AVANCE III console and a triple-resonance cryogenic
probe. Samples were at pH 7.5 in a 25 mM HEPES buffer
containing 100 mM NaCl, 1 mM dithiothreitol, and 1 mM
EDTA. The concentration of 15N labeled RSV N(31-252)
was 0.15 mM. Two-dimensional [15N, 1H] transverse re-
laxation optimized spectroscopy (TROSY) experiments
were recorded with increasing ligand concentration [37].
Evolution times were approximately 53 ms in the 1H di-
mension and 29 ms in the 15N dimension. The total acqui-
sition time was 28 min per experiment.
To estimate the dissociation constant (Kd) from NMR
experiments, 15N-RSV N(31-252) was titrated with a range
of ligand concentrations. The weighted average of chem-
ical shift changes (Δδ(N, H)obs) is calculated using the
following equation:
Δδ N; Hð Þobs ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ΔδHNð Þ2 þ ΔδΝ=5ð Þ2
q
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amide protons and nitrogens, respectively. Then Δδ(N,
H)obs data were fitted by non-linear regression globally
against the total concentration of the subtrate (LT) with
the equation:
Δδ N; Hð Þobs
¼ Δδ N; Hð Þmax
Kd þ LT þ ETð Þ‐
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Kd þ LT þ ETð Þ2−4 LTETð Þ
q
2ET
where Δδ(N, H)max is the maximum chemical shift dif-
ference, ET is the total concentration of N(31-352) in the
solution, and LT is the total concentration of ligand.
DNA manipulations and plasmid construction
Plasmid DNA purification, PCR product purification, and
gel extraction were performed using the QIAprep Spin
Mini Plasmid Purification (Qiagen Inc., Valencia, CA),
QuickStep™2 PCR Purification Kit (EdgeBio, Gaithersburg,
MD), and Rapid Gel Extraction Kit (Marligen Biosciences,
Ijamsville, MD), respectively. Restriction enzymes and
rAPid Alkaline Phosphatase were from Roche Applied
Science (Indianapolis, IN). Primers for PCR DNA were
from Eurofins MWG Operon (Huntsville, AL). All PCRs
were performed with High Fidelity PCR Master (Roche
Applied Science) using reaction conditions specified by
the manufacturer. All ligation reactions were performed
using the Rapid DNA Ligation Kit (Roche Applied Science)
according to the manufacturer’s instructions.
A DNA sequence codon optimized for expression in
E. coli, encoding N-terminal His6-tagged RSV N(13-391)
[strain A2, UniProtKB/Swiss-Prot: NCAP_HRSVA, P03418]
was synthesized and cloned into pET-28b (GenScript,
Piscataway, NJ). The plasmid was named pJT1128.
An expression plasmid was constructed for a N-
terminal His6-tagged RSV N(31-252) as follows. A tobacco
etch virus (TEV) protease cleavage recognition site was
placed before the His6 tag for optional removal. This
was accomplished by amplifying the gene encoding res-
idues (31-252) by PCR from the codon-optimized sequence




PCR product was digested with NdeI and SalI and ligated
into a modified pET-28b plasmid to make plasmid
pJT1324. The ligation mixture was transformed into E.
coli DH5α chemically competent cells (Life Technologies,
Grand Island, NY) and transformants were selected on
Luria-Bertani (LB) agar supplemented with 30 μg/ml
kanamycin. Transformants were analyzed by PCR, and
plasmid DNA was isolated and sequenced for verification.The gene sequence encoding a GST-tagged RSV P(1-241)
construct was synthesized with codon optimization for
expression in E. coli and cloned into pET-30a (BlueSky
Bioservices, Worcester, MA). The plasmid was desig-
nated pJT1200.
The full length coding sequence (residues 1-241) for
the human respiratory syncytial virus phosphoprotein
P [strain A2, UniProtKB/Swiss-Prot: PHOSP_HRSVA,
P03421] was synthesized in vitro by GeneArt AG (Life
Technologies). The sequence was codon-optimized for
Spodoptera frugiperda expression. The synthesized DNA
fragment was restriction-cloned into a modified version of
the pFastBac1 baculovirus expression vector (Life Tech-
nologies), downstream of an N-terminal His10 tag and a
TEV protease cleavage recognition sequence.
Co-expression of RSV N(13-391) and RSV P (1-241)
For protein production, the plasmids pJT1128 and pJT1200
were transformed into E. coli BL21(DE3)pLysS (EMD Che-
micals, Gibbstown, NJ) and plated on LB medium contain-
ing 25 μg/ml kanamycin and 100 μg/ml ampicillin at 37°C
overnight. A single colony of BL21(DE3)pLysS/pJT1128/
pJT1200 was inoculated into a 100-ml culture of LB con-
taining 25 μg/ml kanamycin and 100 μg/ml ampicillin and
grown overnight at 37 °C. The overnight culture was di-
luted to OD600 = 0.1 in 4 × 1 L of LB containing 25 μg/ml
kanamycin and 100 μg/ml ampicillin and grown at 30°C
with aeration to mid-logarithmic phase (OD600 = 0.6). The
culture was incubated on ice for 30 minutes and transferred
to 18°C. IPTG was then added to a concentration of 0.5
mM. After overnight induction at 18°C, the cells were har-
vested by centrifugation at 5,000 g for 15 min at 25°C. Cell
pastes were stored at –20°C.
Purification of RSV N(13-391)
The frozen cell paste from 4 L of cell culture was sus-
pended in 50 ml of Lysis Buffer consisting of 50 mM
Tris-HCl (pH 8.0), 0.5 M NaCl, 5% (v/v) glycerol, and 1
EDTA-free protease inhibitor cocktail tablet (Roche Mo-
lecular Biochemical, Indianapolis IN). Cells were disrupted
by French Press at 18,000 psi twice at 4°C. The crude ex-
tract was centrifuged at 150,000 g for 30 min at 4°C. The
supernatant was applied at a flow rate of 2.0 ml/min onto
a 5-ml HiTrap Ni2+ chelating column (GE Healthcare Life
Sciences, Piscataway NJ) pre-equilibrated with Buffer A
consisting of 50 mM Tris-HCl (pH 8.0), 0.5 M NaCl,
and 5% glycerol. The column was then washed with Buffer
A, and eluted with a linear gradient from 0 to 0.5 M imid-
azole in Buffer A. Fractions containing RSV N(13-391)
were pooled and dialyzed against 1 L of Buffer B consisting
of 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM dithio-
threitol, and 5% glycerol. The dialyzed sample was loaded
at a flow rate of 2.0 ml/min onto a 20-ml Q-Sepharose
HP (HR16/10) column (GE Healthcare Life Sciences)
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with Buffer B and eluted with a linear gradient from 0
to 1 M NaCl in Buffer B. Fractions containing RSV N
(13-391) were pooled and concentrated to 5 ml by Amicon®
Ultracel-10K (Millipore, Billerica, MA). The 5 ml sample
was applied at a flow rate of 1.5 ml/min to a 120-ml Super-
dex 200 (HR 16/60) column (GE Healthcare Life Sciences)
pre-equilibrated and eluted with buffer consisting of 50
mM Tris-HCl (pH 8.0), 0.5 M NaCl, 1 mM EDTA, 1 mM
dithiothreitol, and 5% glycerol. The fractions containing
RSV N(13-391) were pooled and concentrated. The protein
was characterized by SDS-PAGE and LC-MS, and the con-
centration was determined by the Bradford method [38].
The final yield of purified N(13-391) was 30 mg from 4 L
of cell paste. The protein was stored at –80°C. GST-RSV P
(1-241) was not detectably expressed in the cells and none
copurified with RSV-N(13-391). The ratio of UV absorb-
ance at 280 nm to absorbance at 260 nm (A280/A260) was
2.2. No RNA was detected in the N(13-391) protein when
2 μg of protein was run on an agarose gel and stained with
ethidium bromide.
Expression and purification of RSV N (31-252)
The method for overexpression of N (31-252) was the
same as for coexpression of N(13-391) and P (1-241) (see
above), except using only plasmid pJT1324 and omitting
ampicillin. The frozen cell paste from 4 L of cell culture
was suspended in 50 ml of Lysis Buffer consisting of 25
mM HEPES (pH 7.3), 0.5 M NaCl, 5% (v/v) glycerol, and 1
EDTA-free Protease inhibitor cocktail tablet. Cells were
disrupted by French Press at 18,000 psi twice at 4°C. The
crude extract was centrifuged at 150,000 g for 30 min
at 4°C. The supernatant was applied at a flow rate of
2.0 ml/min onto a 5-ml HiTrap Ni2+ chelating column
(GE Healthcare Life Sciences) pre-equilibrated with Buffer
C consisting of 25 mM HEPES (pH 7.3), 0.5 M NaCl, and
5% glycerol. The column was washed with Buffer C, and
eluted with a linear gradient from 0 M to 0.5 M imidazole
in Buffer C. Fractions containing N (31-252) were pooled
and concentrated to 5 ml. The 5-ml sample was applied at
a flow rate of 1.5 ml/min to a 120-ml Superdex 200 (HR
16/60) column pre-equilibrated and eluted with buffer
consisting of 25 mM HEPES (pH 7.3), 0.5 M NaCl, 1 mM
EDTA, 1 mM dithiothreitol, and 5% glycerol. The frac-
tions containing N (31-252) were pooled and concen-
trated. The protein was characterized by SDS-PAGE
and LC-MS, and the concentration was determined by
the Bradford method [38]. The final yield of purified N
(31-252) was 135 mg from 4 L of cell paste. The protein
was stored at –80°C. A280/A260 was 2.6. No RNA was de-
tected in the N(31-252) protein when 2 μg of protein was
run on an agarose gel and stained with ethidium bromide.
Uniformly 15N-labeled N (31-252) was prepared by
growing cells in M9 minimal medium supplemented with1 g/L of [15N] NH4Cl and 10 g/L glucose as the sole nitro-
gen and carbon sources. N (31-252) was purified as de-
scribed above and stored in buffer consisting of 25 mM
HEPES (pH 7.3), 0.1 M NaCl, 1 mM EDTA, and 1 mM
dithiothreitol. The extent of isotope labeling was >93%
15N based on comparison of the observed mass with that
expected from the sequence.Expression and purification of RSV P(1-241)
Routine S. frugiperda (Sf21) cell maintenance, generation
of bacmid DNA, generation of recombinant baculoviruses,
expression studies in 24-deep-well blocks and roller bottles
were carried out essentially as described in [39], except that
no gentamicin antibiotic was added to insect cell cultures.
SF900II medium for Sf21 cells was from Invitrogen. Fetal
bovine serum (FBS) was from PAA Laboratories.
Insect cell pellets from 2 L of culture were thawed from
-80°C and resuspended by homogenization in 150 ml of
Lysis Buffer consisting of 50 mM Tris-HCl (pH 8.0), 300
mM NaCl, 10 mM imidazole, 2 mM tris(2-carboxyethyl)
phosphine (TCEP), 1 mM phenylmethylsulfonyl fluoride
(PMSF), and 3 EDTA-free protease inhibitor tablets
(Roche). Cells were lysed by sonication on ice (5 × 30-s
bursts) and clarified by centrifugation at 50,000 g for 1h at
4°C. The supernatant was loaded at 0.2 ml/min onto a
2-ml column of Ni-NTA Superflow resin (Roche). The
column was washed with lysis buffer followed by buffer D,
consisting of 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10
mM imidazole, and 2 mM TCEP, followed by additional
washes at 20 mM and 40 mM imidazole in buffer D.
Bound protein was eluted with 100% buffer E (buffer D
with 300 mM imidazole). Fractions containing RSV P
protein based on SDS-PAGE were pooled and further
purified by applying at a flow rate of 0.5 ml/min to a
120-ml Superdex 75 (XK26/60) gel filtration column (GE
Healthcare Life Sciences) pre-equilibrated and eluted with
buffer F consisting of 50 mM Tris-HCl (pH 7.4), 200 mM
NaCl, 15% glycerol, and 1 mM TCEP. The fractions with
the highest purity as judged by SDS PAGE were pooled,
snap-frozen in liquid nitrogen at 1.2 mg/ml, and stored
at -80°C. The final yield of purified RSV P(1-241) was ~3
mg/L of cell paste. The His-tag was removed by TEV pro-
tease cleavage with a 1:200 ratio by weight of TurboTEV
(Eton Bioscience, San Diego, CA) to RSV P(1-241) over-
night at 4°C. The protease was removed by adsorption to
immobilized Ni2+ resin.
For the BP5 competition assay, the P protein storage
buffer was replaced by repeated concentration using centri-
fugal ultrafiltration with a Millipore Ultrafree 0.5 unit with
Biomax-10 membrane (EMD Millipore, Billerica, MA) and
dilution with 10 mM Tris-HCl (pH 7.5). The protein
concentration was determined by the method of Bradford
[38] using bovine serum albumin as the standard. Serial
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(pH 7.5) +0.01% Brij-35.
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